Epigral Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/uqm2bwfpnr088bnzu0ljzidg.pdf

Key Takeaways


Volume & Revenue Recovery

Maulik Patel: "We witnessed an improvement from September month onwards and from current business scenario. We believe that the coming quarters would be better than Q2."

Derivatives & Specialty: The Mix Shift


CPVC: Demand & Competitive Position

Maulik Patel: "if it is approved in the fire application, then it will be the huge, huge, huge, application for the Indian market for the infrastructure"

Margins & Profitability


Balance Sheet & Capital Allocation


Long-Term Growth Framework

Milind Kotecha: "INR 5,000 crore is something that we have keep a target to achieve and that's where we are targeting in terms of the CapEx and the volumes... If things move as per our plan, then INR 5,000 crore can be achieved and if the situation is like FY24, which is there right now, then these can be bit lower than what we have given."
Kaushal Soparkar: "the long-term story of India is intact and current situation is short term"

Guidance & Commitments

CommitmentSpecificsTimeline
H2 outperformanceH2 will be definitely better than H1; Q3 and Q4 will improve on every quarterFY24 H2
EBITDA marginFull-year EBITDA margin in the range of 24% to 25%FY24
CPVC capacity expansionExpansion from 30,000 to 45,000 tons completedQ4 FY24
CPVC Compound plant35,000-ton plant commissionedEnd of Q4 FY24
Epichlorohydrin utilizationCapacity utilization to further improveQ3 FY24 onward
Debt levelRemain in range of INR 970–980 crore after Chlorotoluene and CPVC expansionNear term
Meghmani Organics paymentINR 150 crore remaining paid over four yearsOver four years
Captive chlorine consumptionReach up to 80% at full Caustic Soda capacityWhen CPVC expansion and Chlorotoluene plant commission
FY27 revenue targetINR 5,000 crore aspirational; lower if FY24-like situation persistsFY27

Key Metrics

MetricQ2 FY24
Revenue₹479 cr, +5% QoQ, -40% YoY
EBITDA₹108 cr, +13% QoQ, -40% YoY
EBITDA margin23%, vs 21% in Q1 FY24
PAT₹38 cr, +20% QoQ, -58% YoY
Revenue from Derivatives & Specialty46% of total revenue, vs 29% in Q2 FY23 and 37% in Q1 FY24
Volume growth+12% QoQ, +21% YoY; Derivatives & Specialty +37%, Chlor-Alkali +13%
Overall plant capacity utilization77%, vs 71% in Q1 FY24
CPVC capacity utilization80–85%
Epichlorohydrin capacity utilization45–50%
Caustic Soda capacity utilization75–78%
ECU (Chlor-Alkali)₹29,000–30,000, vs ₹28,000–29,000 in Q1 FY24
Captive chlorine consumption~70%
Net debt₹961 cr as on 30 Sep 2023, vs ₹863 cr as on 31 Mar 2023
Net debt to EBITDA1.8x, vs 1.3x in Q2 FY23
Net debt to equity0.9x in Q1 FY24, vs 1x in Q2 FY23
ROC (trailing 12 months)21% including CWIP, 23% excluding CWIP
Capex spent in Q2 FY24₹117 cr
Cost of borrowing8.25%
CPVC price₹135–140 per kg level
EBITDA margin guidance for FY2424–25% (per management)